Pericardial Mesothelioma - Revision history

MesotheliomaSupport: Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

2026-04-06T09:57:10Z

Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

← Older revision		Revision as of 09:57, 6 April 2026
Line 438:		Line 438:
	<ref name="dandell-lawsuit">[https://dandell.com/mesothelioma-lawsuit/ Mesothelioma Lawsuit], Danziger and De Llano, LLP</ref>		<ref name="dandell-lawsuit">[https://dandell.com/mesothelioma-lawsuit/ Mesothelioma Lawsuit], Danziger and De Llano, LLP</ref>
	<ref name="mesotheliomaattorney-claims">[https://mesotheliomaattorney.com/mesothelioma-claims/ Mesothelioma Claims], MesotheliomaAttorney.com</ref>		<ref name="mesotheliomaattorney-claims">[https://mesotheliomaattorney.com/mesothelioma-claims/ Mesothelioma Claims], MesotheliomaAttorney.com</ref>
	~~<ref name="mlc-survival">[https://mesotheliomalawyercenter.org/mesothelioma/prognosis/ Mesothelioma Prognosis and Survival Rates], Mesothelioma Lawyer Center</ref>~~
	</references>		</references>

MesotheliomaSupport: Update epidemiology data: asbestos link %, autopsy rate, sex ratio, annual cases per Marinaccio 2020/Stella 2025 Italian registry data

2026-03-13T17:22:34Z

Update epidemiology data: asbestos link %, autopsy rate, sex ratio, annual cases per Marinaccio 2020/Stella 2025 Italian registry data

Show changes

MesotheliomaSupport: Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

2026-03-08T21:53:44Z

Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

Show changes

MesotheliomaSupport: Add at-a-glance listicle between lead section and Key Facts to fill blank space beside infobox

2026-02-24T05:21:35Z

Add at-a-glance listicle between lead section and Key Facts to fill blank space beside infobox

← Older revision		Revision as of 05:21, 24 February 2026
Line 56:		Line 56:

	The disease presents unique medical and legal challenges. Medically, the nonspecific cardiac symptoms it produces — chest pain, shortness of breath, pericardial effusion — lead to frequent misdiagnosis and diagnostic delays, with '''more than 75% of cases discovered only at autopsy'''. Legally, the weaker and more controversial relationship between asbestos exposure and pericardial mesothelioma creates additional evidentiary complexities for patients seeking compensation. Despite these challenges, recent data from Memorial Sloan Kettering Cancer Center demonstrate that aggressive trimodality therapy can achieve '''median overall survival of 70.3 months''' — nearly 6 years — compared to 8.2 months without trimodality treatment.<ref name="offin-msk" /><ref name="mcgehee-asco" /><ref name="mlc-pericardial" />		The disease presents unique medical and legal challenges. Medically, the nonspecific cardiac symptoms it produces — chest pain, shortness of breath, pericardial effusion — lead to frequent misdiagnosis and diagnostic delays, with '''more than 75% of cases discovered only at autopsy'''. Legally, the weaker and more controversial relationship between asbestos exposure and pericardial mesothelioma creates additional evidentiary complexities for patients seeking compensation. Despite these challenges, recent data from Memorial Sloan Kettering Cancer Center demonstrate that aggressive trimodality therapy can achieve '''median overall survival of 70.3 months''' — nearly 6 years — compared to 8.2 months without trimodality treatment.<ref name="offin-msk" /><ref name="mcgehee-asco" /><ref name="mlc-pericardial" />

			'''Understanding pericardial mesothelioma at a glance:'''
			* '''Rarest mesothelioma type''' — less than 1% of all mesothelioma diagnoses worldwide<ref name="rjae279-oxford" />
			* '''75% discovered at autopsy''' — cardiac symptoms mimic pericarditis, tamponade, and heart failure<ref name="rjae279-oxford" />
			* '''Controversial asbestos link''' — only 20–25% of patients have documented asbestos exposure histories<ref name="mcgehee-asco" />
			* '''200–350 total cases''' reported in the entire medical literature since first description<ref name="rjae279-oxford" />
			* '''Trimodality therapy breakthrough''' — MSK data shows 70.3-month median survival versus 8.2 months without<ref name="offin-msk" />
			* '''Chemotherapy benefit''' — cisplatin-pemetrexed achieves 13-month median survival in systematic review<ref name="mcgehee-pubmed" />
			* '''Epithelioid predominant''' — approximately 75% of cases are the epithelioid histologic subtype<ref name="ihc-panel" />
			* '''No dedicated staging system''' — no TNM classification exists specific to pericardial mesothelioma<ref name="offin-msk" />
			* '''Molecular overlap''' — shares BAP1, CDKN2A, NF2, and TP53 alterations with [[Pleural Mesothelioma\|pleural mesothelioma]]<ref name="schoenfeld" />
			* '''Legal complexity''' — weaker asbestos causation evidence creates additional challenges for [[Mesothelioma Settlements\|compensation claims]]<ref name="dandell" />

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Layout fix: moved overview to lead section (flows beside infobox), removed redundant H1, eliminated blank space issue

2026-02-24T05:02:51Z

Layout fix: moved overview to lead section (flows beside infobox), removed redundant H1, eliminated blank space issue

← Older revision		Revision as of 05:02, 24 February 2026
Line 6:		Line 6:
	\|published_time=2026-02-23		\|published_time=2026-02-23
	}}		}}

	~~= Pericardial Mesothelioma =~~

	{\| class="wikitable" style="float:right; margin:0 0 1em 1em; width:300px; border:2px solid #1a5276;"		{\| class="wikitable" style="float:right; margin:0 0 1em 1em; width:300px; border:2px solid #1a5276;"
Line 52:		Line 50:
	\| style="padding:8px;" \| None specific to pericardial mesothelioma		\| style="padding:8px;" \| None specific to pericardial mesothelioma
	\|}		\|}

			'''Pericardial mesothelioma''' is a rare and aggressive cancer that originates in the '''pericardium''', the double-layered serous membrane that surrounds the heart and the roots of the great vessels. The pericardium consists of an inner visceral layer (epicardium) directly adherent to the heart muscle and an outer parietal layer, with the pericardial cavity between them containing a small amount of lubricating fluid. Pericardial mesothelioma arises from the mesothelial cells lining these surfaces and can involve either or both layers, eventually encasing the heart and restricting cardiac function.<ref name="pmc-tamponade" /><ref name="rjae279-oxford" />

			Among the four recognized types of mesothelioma — [[Pleural Mesothelioma\|pleural]], [[Peritoneal Mesothelioma\|peritoneal]], pericardial, and [[Testicular Mesothelioma\|testicular (tunica vaginalis)]] — the pericardial form is the least common and the most diagnostically challenging. Accounting for '''less than 1% of all mesothelioma diagnoses''', with only an estimated 200–350 total cases ever reported in the medical literature, its extreme rarity has prevented the development of randomized clinical trials, standardized staging systems, or consensus treatment guidelines. Clinical management is guided almost entirely by case reports, small institutional series, and extrapolation from the far more common pleural mesothelioma.<ref name="offin-msk" /><ref name="mcgehee-pubmed" /><ref name="rjae279-oxford" />

			The disease presents unique medical and legal challenges. Medically, the nonspecific cardiac symptoms it produces — chest pain, shortness of breath, pericardial effusion — lead to frequent misdiagnosis and diagnostic delays, with '''more than 75% of cases discovered only at autopsy'''. Legally, the weaker and more controversial relationship between asbestos exposure and pericardial mesothelioma creates additional evidentiary complexities for patients seeking compensation. Despite these challenges, recent data from Memorial Sloan Kettering Cancer Center demonstrate that aggressive trimodality therapy can achieve '''median overall survival of 70.3 months''' — nearly 6 years — compared to 8.2 months without trimodality treatment.<ref name="offin-msk" /><ref name="mcgehee-asco" /><ref name="mlc-pericardial" />

	== Key Facts ==		== Key Facts ==
Line 70:		Line 74:
	* Molecular studies have revealed that pericardial mesothelioma shares the same tumor suppressor inactivation patterns as pleural mesothelioma, including recurrent alterations in CDKN2A, BAP1, NF2, and TP53<ref name="schoenfeld" />		* Molecular studies have revealed that pericardial mesothelioma shares the same tumor suppressor inactivation patterns as pleural mesothelioma, including recurrent alterations in CDKN2A, BAP1, NF2, and TP53<ref name="schoenfeld" />
	\|}		\|}

	~~== Overview ==~~

	Pericardial mesothelioma is a rare and aggressive cancer that originates in the pericardium, the double-layered serous membrane that surrounds the heart and the roots of the great vessels. The pericardium consists of an inner visceral layer (epicardium) directly adherent to the heart muscle and an outer parietal layer, with the pericardial cavity between them containing a small amount of lubricating fluid. Pericardial mesothelioma arises from the mesothelial cells lining these surfaces and can involve either or both layers, eventually encasing the heart and restricting cardiac function.<ref name="pmc-tamponade" /><ref name="rjae279-oxford" />

	Among the four recognized types of mesothelioma — [[Pleural Mesothelioma\|pleural]], [[Peritoneal Mesothelioma\|peritoneal]], pericardial, and [[Testicular Mesothelioma\|testicular (tunica vaginalis)]] — the pericardial form is the least common and the most diagnostically challenging. Its extreme rarity has prevented the development of randomized clinical trials, standardized staging systems, or consensus treatment guidelines. Instead, clinical management is guided almost entirely by case reports, small institutional series, and extrapolation from the far more common pleural mesothelioma.<ref name="offin-msk" /><ref name="mcgehee-pubmed" />

	The disease presents unique medical and legal challenges. Medically, the nonspecific cardiac symptoms it produces — chest pain, shortness of breath, pericardial effusion — lead to frequent misdiagnosis and diagnostic delays, with the majority of cases discovered only at autopsy. Legally, the weaker and more controversial relationship between asbestos exposure and pericardial mesothelioma creates additional evidentiary complexities for patients seeking compensation. Despite these challenges, emerging evidence suggests that aggressive multimodality treatment at specialized centers can significantly improve outcomes for selected patients.<ref name="offin-msk" /><ref name="mcgehee-asco" /><ref name="mlc-pericardial" />

	== How Common Is Pericardial Mesothelioma? ==		== How Common Is Pericardial Mesothelioma? ==

MesotheliomaSupport: New page: Comprehensive pericardial mesothelioma guide covering epidemiology, asbestos causation controversy, symptoms, diagnostic workup with IHC panel, trimodality therapy (MSK 70.3-month data), prognosis, comparison with other types, legal implications — 31 references, 7 FAQs, 10 categories

2026-02-24T04:38:04Z

New page: Comprehensive pericardial mesothelioma guide covering epidemiology, asbestos causation controversy, symptoms, diagnostic workup with IHC panel, trimodality therapy (MSK 70.3-month data), prognosis, comparison with other types, legal implications — 31 references, 7 FAQs, 10 categories

Show changes